Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Wednesday, November 21, 2018 · 468,959,886 Articles · 3+ Million Readers

Radiopharmaceuticals (Nuclear Medicine) Market 2018 Global Share,Trend,Segmentation and Forecast to 2023

PUNE, INDIA, February 14, 2018 /EINPresswire.com/ --

WiseGuyReports.Com Publish a New Market Research Report On –“ Radiopharmaceuticals (Nuclear Medicine) Market 2018 Global Share,Trend,Segmentation and Forecast to 2023”.

Description:

Global Radiopharmaceuticals (Nuclear Medicine) Market: By Product Type (Diagnostic Radiopharmaceuticals (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals) and Therapeutic Radiopharmaceuticals (Beta Emitters, Alpha emitters, Brachytherapy, and Others)), By Application (Oncology, Neurological disorders, Cardiovascular diseases, Thyroid, and Others), By Route of Administration (Oral, Inhalation, and Parenteral) By End User (Hospitals, Clinics, Diagnostic Centers, and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Radiopharmaceuticals (Nuclear Medicine) Market Outline:

Global radiopharmaceuticals (nuclear medicine) market report gives a comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application area, route of administration, end user, and geographic regions. This report studies Global radiopharmaceuticals (nuclear medicine) market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed radiopharmaceuticals market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the Global radiopharmaceuticals (nuclear medicine) market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescribing of radiopharmaceuticals.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/2984802-radiopharmaceuticals-nuclear-medicine-market-global-market-estimation-dynamics

For more information or any query mail at sales@wiseguyreports.com

Radiopharmaceuticals (Nuclear Medicine) Market:

Global radiopharmaceuticals (nuclear medicine) market estimated to be valued US$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. The market for radiopharmaceuticals projected to reach US$ 8,564 Mn by 2023 owing to increasing adoption of radiotherapeutic and diagnostic procedures across the globe.

Growing prevalence of cancer and cardiovascular diseases expected to drive adoption of radiopharmaceuticals across the globe

The global radiopharmaceuticals (nuclear medicine) market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted in an increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radioimmunotherapies expected to drive the overall market revenue growth over the forecast period

Emergence of radiopharmaceuticals (nuclear medicine) as safer alternative to the conventional diagnosis
The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as an effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.

North America accounts for larger revenue share in global radiopharmaceuticals (nuclear medicine) market
North America market holds the higher revenue share in global radiopharmaceuticals (nuclear medicine) market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia Pacific radiopharmaceuticals (nuclear medicine) market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region

Competition Assessment

Key players profiled in the global radiopharmaceuticals (nuclear medicine) market include:
Advanced Accelerator Applications S.A. (France)
Bayer AG (Germany)
Bracco Imaging S.p.A (Italy)
Cardinal Health, Inc. (U.S.)
Eli Lilly and Co. (U.S.)
GE Healthcare (U.S.)
IBA Molecular Imaging (Belgium)
Jubilant Life Sciences Ltd (India)
Lantheus Medical Imaging, Inc. (U.S.)
Mallinckrodt plc (Ireland)
Navidea Biopharmaceutical (U.S.)
Nordion, Inc. (Canada)
Siemens Healthineers (Germany)

Players in the radiopharmaceuticals (nuclear medicine) market are focusing on expanding product portfolio, acquisitions to garner larger market revenue share in global radiopharmaceuticals (nuclear medicine) market

Report Details @ https://www.wiseguyreports.com/reports/2984802-radiopharmaceuticals-nuclear-medicine-market-global-market-estimation-dynamics

Table Of Contents – Major Key Points

1. Executive Summary

2. Global Radiopharmaceuticals (Nuclear Medicine) Market Introduction
2.1. Global Radiopharmaceuticals (Nuclear Medicine) Market – Taxonomy
2.2. Global Radiopharmaceuticals (Nuclear Medicine) Market –Definitions
2.2.1. Product Type
2.2.2. Application
2.2.3. Route of Administration
2.2.4. End-User

3. Global Radiopharmaceuticals (Nuclear Medicine) Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Factors Impact Analysis
3.6. Global Radiopharmaceuticals (Nuclear Medicine) Market – Regulations
3.6.1. U.S.
3.6.2. Europe

4. Global Radiopharmaceuticals (Nuclear Medicine) Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. Global Radiopharmaceuticals (Nuclear Medicine) Market, By Product Type, 2012 - 2016 and Forecast, 2017 - 2023
5.1. Diagnostic Radiopharmaceuticals
5.1.1. SPECT Radiopharmaceuticals
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. PET Radiopharmaceuticals
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis

Continue……

For more information or any query mail at sales@wiseguyreports.com

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire